Altrius Capital Management Inc lifted its stake in Roche Holding AG (OTCMKTS:RHHBY - Free Report) by 6.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 224,804 shares of the company's stock after acquiring an additional 12,646 shares during the period. Roche makes up about 2.0% of Altrius Capital Management Inc's holdings, making the stock its 12th largest holding. Altrius Capital Management Inc's holdings in Roche were worth $7,794,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors have also recently made changes to their positions in RHHBY. AlphaMark Advisors LLC bought a new stake in Roche during the first quarter valued at $34,000. GAMMA Investing LLC boosted its stake in Roche by 61.5% during the second quarter. GAMMA Investing LLC now owns 5,038 shares of the company's stock valued at $175,000 after buying an additional 1,919 shares during the period. Archer Investment Corp boosted its stake in Roche by 10.6% during the second quarter. Archer Investment Corp now owns 6,810 shares of the company's stock valued at $236,000 after buying an additional 652 shares during the period. Waldron Private Wealth LLC bought a new stake in Roche during the second quarter valued at $263,000. Finally, Lee Danner & Bass Inc. purchased a new stake in Roche during the second quarter valued at about $327,000.
Roche Stock Performance
Roche stock traded up $0.28 during trading hours on Thursday, hitting $39.61. 1,155,246 shares of the stock traded hands, compared to its average volume of 2,316,393. The firm's 50-day moving average price is $39.89 and its two-hundred day moving average price is $34.97. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.04 and a current ratio of 1.35. Roche Holding AG has a one year low of $29.20 and a one year high of $42.43.
Analyst Upgrades and Downgrades
RHHBY has been the topic of a number of research reports. The Goldman Sachs Group initiated coverage on Roche in a research report on Thursday, May 30th. They set a "sell" rating on the stock. Deutsche Bank Aktiengesellschaft downgraded Roche from a "hold" rating to a "sell" rating in a research report on Friday, September 13th. Finally, Bank of America upgraded Roche from a "neutral" rating to a "buy" rating in a report on Friday, September 13th. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, Roche has a consensus rating of "Hold".
Read Our Latest Analysis on Roche
About Roche
(
Free Report)
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.
Featured Articles
Before you consider Roche, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roche wasn't on the list.
While Roche currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
